38
64000-00120 Rev 3
Acute migraine headache clinical study
Clinical data demonstrating the safety and effectiveness of gammaCore for the acute treatment of
migraine headache is presented from one prospective, double-blind, sham-controlled, randomized
clinical trial (The PRESTO Study).
Summary
This randomized sham-controlled trial demonstrated the safety and efficacy of gammaCore for the
acute treatment of episodic migraine with or without aura. gammaCore was safe and well tolerated in
this study.
gammaCore for the acute treatment of migraine headache: The PRESTO Study
In the PRESTO Study, subjects were instructed to treat their migraine headache within twenty minutes
of the onset of pain. Each self-administered treatment consisted of bilateral 120-second stimulations to
the right and left sides of the neck. If the pain had not decreased fifteen minutes after initial treatment,
subjects were instructed to repeat the bilateral stimulations, and if not pain-free two hours after initial
treatment, a third set of bilateral stimulations was allowed.
Figure 5. PRESTO Treatment Protocol
Demographics
The PRESTO study enrolled a total of 243 patients with migraine. General demographics are
provided in the following table:
Note: The remainder of this page was intentionally left blank.